Web19 okt. 2024 · SHENZHEN, China, Oct. 19, 2024 /PRNewswire/ -- SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (hereinafter referred to as: CHIPSCREEN), a China headquartered biopharmaceutical company developing and marketing novel drugs based on its unique technology of Chemical Genomics Drug discovery platform, today … Web16 apr. 2024 · SHENZHEN, China, April 16, 2024 /PRNewswire/ -- Shenzhen Chipscreen Biosciences, a China headquartered biopharmaceutical company developing and ma...
Ovarian Cancer Clinical Trials A Drug Pipeline Analysis
Web1 dec. 2024 · SHENZHEN, China, Dec. 1, 2024 /PRNewswire/ -- Shenzhen Chipscreen Biosciences' licensing partner, HUYABIO International (HUYABIO™), today announced the regulatory approval for Chidamide (Tucidinostat, also known as Epidaza ®, Hiyasta®, HBI-8000) monotherapy for the treatment of relapsed or refractory (R/R) PTCL by the Ministry … Web27 feb. 2024 · “Chipscreen Biosciences and Chipscreen NewWay have extensive experience in clinical drug development and commercialization,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “With this agreement in place, we will work together to accelerate YH008’s entry into the market to benefit patients.” lally srl
Xian-ping Lu - Chairman & Chi.. - Chipscreen Biosciences
Web28 mrt. 2024 · Company summary. Overview. Shenzhen Chipscreen Biosciences (微芯 … Web深圳市南山区高新中一道生物孵化器大楼 2号楼601-606室 北京市朝阳区农展馆南路13号瑞辰国际中心1207室 生产基地:四川省成都市高新西区康强一路298号 WebShenzhen Chipscreen Biosciences Co Ltd is engaged in the research and development of small molecule drugs. Contact Information Website www.chipscreen.com Formerly Known As Microchip Ownership Status Publicly Held Financing Status Formerly VC-backed Primary Industry Drug Discovery Other Industries Biotechnology Stock Exchange SHG Primary … lally southpoint ford staff